Human Genome Sciences (NASDAQ: HGSI) announced that it is being acquired by GlaxoSmithKline Plc in a deal that is worth roughly $3 billion after a previous offer by GSK was rejected.

• Do you own shares of Human Genome Sciences (NASDAQ: HGSI)?

• Did you buy HGSI shares before July 16, 2012?

• Do you think that the proposed deal is unfair to Human Genome Sciences (NASDAQ: HGSI) shareholders? Is $14.25 in cash too low for Human Genome Sciences (NASDAQ: HGSI)?

Think this deal is unfair? Call 1-800-934-2921 right now to protect your rights.

If you own any amount of HGSI shares, contact our law firm today to protect your rights.

Own shares of HGSI and think that $14.25 is too low? Our law firm is investigating potential claims against the board of directors of HGSI concerning possible breaches of fiduciary duty and other violations of securities laws related to the agreement to be purchased by GlaxoSmithKline Plc in a deal that is worth roughly $3 billion after a previous offer by GSK was rejected.

Own HGSI stock?

If you are a shareholder of any amount of HGSI complete the form on this page or call Attorney Bill Kyros at 1-800-934-2921 to discuss your rights.

Kyros Law LLP is a Boston-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions.

Human Genome Sciences (NASDAQ: HGSI) is a biopharmaceutical corporation founded in 1992. It uses the human DNA sequence to develop protein and antibody drugs. As of 2008, it has drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax disease, and cancer.